Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Lillian Werner(Dana-Farber Cancer Institute), Leandra Cole(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Poorvi Somaiya Dutt(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Richard M. Stone(Dana-Farber Cancer Institute), Mary Paty Bryant(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Emma Logan(Beth Israel Deaconess Medical Center), Max Coll(Beth Israel Deaconess Medical Center), David P. Steensma(Harvard University), Dina Stroopinsky(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Kristen Palmer(Beth Israel Deaconess Medical Center), Ayad Hamdan(University of California San Diego), Donna Neuberg(Otsuka (Japan)), Abigail Washington(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center)
Cited by 165
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k